Ok maxter, add my input for the holders too.
The receptor fatality causation (oestrogen) data was the standout result.
This, of course, was known by our world class scientists as a trend on the release or the interim results, hence the current Phase 2 design of study.
Adding to my posts from yesterday, need to also commend the articulation of the report and PR (investor presentation) that I have been critical of in the past.
Time to accumulate some more (IMO).
PTX Price at posting:
12.0¢ Sentiment: Buy Disclosure: Held
